Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its drug candidate SHR-A1921 is on track to receive breakthrough therapy designation (BTD) from the National Medical Products Administration (NMPA) for the treatment of platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
SHR-A1921 is an antibody drug conjugate (ADC) developed in-house by Jiangsu Hengrui, targeting TROP2. The drug is designed to bind to the target antigen on the surface of tumor cells, facilitating endocytosis of the drug into the cell and subsequent release of small-molecule toxins to eliminate tumor cells. Previously, SHR-A1921 earned a fast-track designation (FTD) from the US Food and Drug Administration (FDA) for the same indications.- Flcube.com
